Vivesto

Vivesto is a specialty pharmaceutical company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs.

[Vivesto @VivestoAB]

We published our Q2 results today, which show continued cost control, with a reduction in operating expenses.

https://t.co/r1HWTqliL2

#oncology #biotech

[Vivesto @VivestoAB]

For #investors and #media:

Today Inceptua launched Apealea® in Germany. This is great news for patients but also for Vivesto’s business as we are eligible for royalties on any sales.

https://t.co/NuAHyDHsAS

#oncology #biotech

[Vivesto @VivestoAB]

This #MensHealthWeek have a look at this campaign by @menshealthforum all about how to carry out a MAN-MOT. Your car gets one regularly so why not all men? This article shows how to do your own and help early diagnosis of Prostate cancer.
Read more here: https://t.co/1zrgMV9Fui

[Vivesto @VivestoAB]

It’s #MensHealthWeek from 13-19 June and we are proud to play our part in tackling advanced prostate cancer, with an investigator-initiated Phase 1b trial Docetaxel Micellar underway.
Join the fight against prostate cancer and click here to find out more: https://t.co/zQGNvVSET5

[Vivesto @VivestoAB]

Today we held our #AGM, at which all resolutions were passed.

We are pleased to welcome Pål Ryfors and Roger Tell as new Board members, with current Board member Peter Zonabend stepping up to the role of Chairman.

#AGM #oncology #specialtypharma

[Vivesto @VivestoAB]

Today we published our Q1 #Financial #Results.

In a challenging financial climate, we were pleased to successfully raise SEK 151m during the quarter and report operational progress on several fronts.

https://t.co/bbJZoJ0kKu

#oncology #biotech

[Vivesto @VivestoAB]

Did you know that #WorldOvarianCancerDay is on May 8? We are proud to be developing new treatments that we hope may make a difference to patients. Learn more about ovarian cancer and check out its symptoms here: https://t.co/56we4phM4Z
#WOCD2022 #NoWomanLeftBehind

[Vivesto @VivestoAB]

Today our CEO, Francois Martelet, presented an update on our evolving business at the #Anglonordic Life Science Conference, which brings together European investors and R&D companies from the Nordics and the UK.

https://t.co/7xSKzCMF4K

#oncology #biotech

[Vivesto @VivestoAB]

Today, we signed a research agreement with Visikol Inc., a leading U.S. #CRO, to evaluate the cellular effects of anti-cancer drug formulations developed using our proprietary XR-17™ and XR-18 technologies.

https://t.co/RLQZQfCusf

#oncology #biotech

[Vivesto @VivestoAB]

Today we announced the appointment of Daniel Tesfa, our new #CMO. Daniel brings extensive experience in clinical development and precision oncology over 20 years.

Read the full announcement here:

https://t.co/vKojrFE40e

#oncology #biotech

[Vivesto @VivestoAB]

We have an exciting future epitomised by our new name Vivesto, approved by the Swedish Companies Registration Office today.

The name ‘Vivesto’ comes from Vivo (to live) and esto (this) in Spanish and highlights our purpose of investing in life.

https://t.co/MGpGq3kIwN
#biotech

[Vivesto @VivestoAB]

We’ve announced completion of our rights issue. It will help fund existing operations and our ability to support patients by driving and expanding our innovative oncology pipeline.

https://t.co/MVgrxL6DHV

#biotech #oncology

[Vivesto @VivestoAB]

Today we are attending Vator Swiss Nordic Bio 2022.

We look forward to connecting with likeminded life science professionals from Swiss and Nordic #biotech start-ups, pharmaceutical companies and investors.

https://t.co/ZoP5qPvwOn

#oncology #swissnordicbio #conference

[Vivesto @VivestoAB]

Today we signed a large-scale manufacturing global agreement with @LonzaGroup, for our ovarian cancer drug candidate, #Cantrixil, as we plan for the initiation of a Phase II clinical trial.

Read the full announcement here:

https://t.co/9IxTDs4sT7

#oncology #biotech

[Vivesto @VivestoAB]

Dr. James Garner, CEO of @KaziaTx, explains why they chose to out license their product, Cantrixil, to Oasmia in this recent interview:

https://t.co/vlHgzsVH1x

#oncology #biotech

[Vivesto @VivestoAB]

Yesterday, our CEO Francois Martelet caught up with biotech analyst Klas Pelin at Erik Penser Bank to discuss our rapidly evolving business.
Watch the full interview here: https://t.co/Fv4gtrROG0

#oncology #biotech

[Vivesto @VivestoAB]

Yesterday we announced our Q4 results.

Our work to build a #Nordic oncology powerhouse continues following a year of sustained progress, with our rights issue and name change well underway.

https://t.co/FFngWyOEBi

#oncology #biotech

[Vivesto @VivestoAB]

Today we are pleased to announce our EGM has approved our new name, ‘Vivesto’, which comes from Vivo (to live) and esto (this) in Spanish and suggests investment in life.

https://t.co/TAVBUo1UqA

#biotech #oncology

[Vivesto @VivestoAB]

Please join us in congratulating Kai Wilkinson, who has been promoted to the role of Chief Technology Officer and has joined Oasmia’s Management team.
#biotech #oncology

[Vivesto @VivestoAB]

It is estimated that there will be 34,130 deaths globally from prostate cancer this year.

We are developing Docetaxel micellar specifically for late stage and hard-to-treat prostate cancer, find out more here:

https://t.co/G8bzQ2bzwi

#prostatecancer #biotech #oncology